Boston Immune Technologies & Therapeutics

Executive Summary

Boston Immune Technologies & Therapeutics (BITT) is a biotechnology company pioneering novel immunotherapies based on its proprietary TrapMAb platform, which targets the Tumor Necrosis Factor Receptor (TNFR) superfamily. Founded in 2017 and headquartered in Boston, BITT is developing monoclonal antibodies designed as antagonists for both oncology and autoimmune/inflammatory indications. The TrapMAb technology aims to overcome limitations of existing TNF-targeting therapies by providing improved selectivity and reduced toxicity. While the company is still in early development stages with no disclosed pipeline advancements, its differentiated approach addresses a validated target space with significant market potential. The company remains private with limited public information, suggesting it may be focusing on research and early preclinical studies before advancing to clinical trials.

Upcoming Catalysts (preview)

• Q2 2027Preclinical Proof-of-Concept Data Release40% success
• Q4 2027IND Filing for Lead Oncology Candidate25% success
• Q3 2027Partnership or Licensing Deal15% success